Abstracts tagged "Atherosclerosis"

Abstract Number: 2546 • 2017 ACR/ARHP Annual Meeting
Secukinumab Decreases Arterial Wall Inflammation in Patients with Peripheral Spondyloarthritis
Leonieke van Mens¹, Simone Verweij², Arno van Kuijk³, Erik Stroes² and Dominique Baeten¹, ¹AMC, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ²Vascular Medicine, Academisch Medisch Centrum, Amsterdam, Netherlands, ³Reade, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Patients with spondyloarthritis (SpA), a chronic inflammatory disease, have an increased cardiovascular risk, which is partly due to increased inflammatory activity in the arterial…
Abstract Number: 2656 • 2017 ACR/ARHP Annual Meeting
Alterations of the Splicing Machinery Components in Leukocytes from Systemic Lupus Erythematosus Patients Influences Its Development and Atherothrombotic Profile and Drives the Therapeutic Response
Carlos Perez-Sanchez¹, Maria Ángeles Aguirre Zamorano¹, Sergio Pedraza-Arévalo², Mercedes del Río-Moreno², Irene Cecchi³, Patricia Ruiz-Limon⁴, Nuria Barbarroja¹, Yolanda Jiménez-Gómez¹, Ivan Arias de la Rosa⁴, Maria Carmen Abalos-Aguilera⁴, Pedro Segui⁵, Eduardo Collantes-Estévez¹, Justo P Castaño², Raul M Luque⁶, Maria Jose Cuadrado⁷ and Chary Lopez-Pedrera¹, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Department of Cell Biology, Physiology and Immunology. University of Cordoba, Reina Sofia Hospital, IMIBIC, CIBERobn, and ceiA3, Córdoba, Spain, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁵Radiology, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁶Department of Cell Biology, Physiology and Immunology. University of Cordoba, Hospital Universitario Reina Sofia (HURS), Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), CIBERobn, and ceiA3, Córdoba, Spain, ⁷St Thomas Hospital, Lupus Research Unit, London, United Kingdom
Background/Purpose: Recent studies emphasize the relevance of alternative splicing in the development of genetic and autoimmune diseases. The aim of this study was to identify…
Abstract Number: 2965 • 2017 ACR/ARHP Annual Meeting
Non-Invasive Imaging Methods for Evaluating the Cardiovascular Involvement in Patients with Rheumatoid Arthritis before and after 18 Months of Treatment with Anti-TNF Drugs
Fabiola Atzeni¹, Luigi Gianturco², Laura Boccassini³, Piercarlo Sarzi-Puttini³ and Maurizio Turiel⁴, ¹Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ²Beato Matteo” Hospital, GSD Foundation, Vigevano, Italy, Vigevano, Italy, ³Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, ⁴IRCCS, Galeazzi Orthopedic Institute, Dept. Biomedical Sciences for Health, University of Milan, Milan, Italy
Background/Purpose: The aim of this study was to evaluate left ventricular myocardial function with two- dimensional speckle tracking echocardiography (STE), in addition to conventional Doppler…
Abstract Number: 87 • 2017 Pediatric Rheumatology Symposium
Assessment of Endothelial Dysfunction and Atherogenic Risk Factors in Children with Juvenile Dermatomyositis
Dawn Wahezi¹, Emily Liebling², Jillian Parekh², Marija Dionizovik-Dimanovski¹, Jaeun Choi³ and Qi Gao³, ¹Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ²Pediatrics, Children's Hospital at Montefiore, Bronx, NY, ³Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Endothelial pulse amplitude testing (Endo-PAT) measures changes in vascular tone by post-occlusive hyperemic response. A reduced hyperemic response suggests endothelial dysfunction and serves as…
Abstract Number: 1663 • 2016 ACR/ARHP Annual Meeting
Assessment of Serum Calprotectin and Osteoprotegerin Levels in a Cohort of Spanish Patients with Axial Spondyloarthritis
Fernanda Genre¹, Carlos Fernández-Díaz¹, Javier Rueda-Gotor¹, Raquel López-Mejías¹, Sara Remuzgo-Martínez¹, Begoña Ubilla¹, Veronica Mijares¹, Alfonso Corrales¹, Virginia Portilla¹, Patricia Fuentevilla¹, Luis Rodriguez-Rodriguez², Ricardo Blanco¹, José Luis Hernandez³ and Miguel Angel Gonzalez-Gay^1,4,5, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ²Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ³Bone Metabolism Unit, Department of Internal Medicine, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, RETICEF, Santander, Spain, ⁴School of Medicine, University of Cantabria, Santander, Spain, ⁵Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Calprotectin is a protein involved in several cellular processes including immunomodulation1. Elevated levels of this protein have been observed in inflammatory diseases, since it…
Abstract Number: 1676 • 2016 ACR/ARHP Annual Meeting
Methotrexate and Anti-Tumor Necrosis Treatment Improve Endothelial Function in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Gia Deyab¹, Ingrid Hokstad², Stefan Agewall³, Torstein Lyberg⁴, Jon Elling Whist⁵, Milada Cvancarova Småstuen⁶, Gunnbjørg Hjeltnes⁷ and Ivana Hollan^8,9,10,11, ¹Department of Medical Biochemistry, Innlandet Hospital Trust, Lillehammer, Norway, ²Lillehammer Hospitat for Rheumatic Diseases, Lillehammer, Norway, ³University of Oslo, Oslo, Norway, ⁴Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, ⁵Innlandet Hospital Trust, Lillehammer, Norway, ⁶Institution of health care - Health science PhD program, Oslo and Akershus University College, Oslo, Norway, ⁷Medicine, Innlandet Hospital Trust, Lillehammer, Norway, ⁸Harvard Medical School, Boston, MA, ⁹Department of Medicine, Brigham and Women's Hospital, Boston, MA, ¹⁰Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ¹¹Innlandet Hospital Trust, Brumunddal, Norway
Background/Purpose: Inflammatory rheumatic diseases (IRDs) are associated with accelerated atherosclerosis, which progression is related to inflammation (1). One of the first stages in atherogenesis is…
Abstract Number: 1682 • 2016 ACR/ARHP Annual Meeting
Tnfα Inhibitors Are Associated with Reduced Progression of Carotid Atherosclerotic Plaques By Ultrasound and an Improvement in Aortic Arch Vascular Inflammation By 18-FDG PET/CT in Psoriasis and Psoriatic Arthritis Patients – a Prospective Study from Two Cohorts
Lihi Eder¹, Aditya Joshi², Vinod Chandran³, Amit Dey⁴, Richard J. Cook⁵, Abhishek Chaturvedi⁶, Dafna D. Gladman⁷ and Nehal Mehta⁸, ¹Medicine, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ²National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴National Institutes of Health, Bethesda, MD, ⁵Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁶National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, ⁷Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁸National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Psoriasis (PSO) and psoriatic arthritis (PsA) are chronic inflammatory diseases which are associated with increased cardiovascular (CV) diseases. Observational studies have found that TNFα…
Abstract Number: 1770 • 2016 ACR/ARHP Annual Meeting
The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the First 10 Years
Murray Urowitz¹, Dafna D Gladman², Nicole Anderson³, Jiandong Su⁴ and The Systemic Lupus International Collaborating Clinics (SLICC) Group , ¹Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the first 10 years Background/Purpose: The Medical Outcome Survey Short Form…
Abstract Number: 1786 • 2016 ACR/ARHP Annual Meeting
Long-Term Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus in a Large Case Control Cohort Study
Konstantinos Tselios¹, Dafna D Gladman², Jiandong Su³, Olga Ace⁴ and Murray Urowitz⁵, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Certain traditional and disease-related factors have been identified to accelerate atherosclerosis in systemic lupus erythematosus (SLE). Due to the lack of long-term prospective studies,…
Abstract Number: 1790 • 2016 ACR/ARHP Annual Meeting
Accrual of Disease Comorbidities over 8 Years in a Multicentre Inception SLE Cohort
Murray Urowitz¹, Dafna D Gladman², Nicole Anderson³, Jiandong Su⁴ and The Systemic Lupus International Collaborating Clinics (SLICC) Group, ¹Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The annual accrual of comorbidities in patients with SLE is not well described. We report the annual occurrence of these features in an inception…
Abstract Number: 738 • 2016 ACR/ARHP Annual Meeting
Preventive Effect of Combined Treatment with Bisphosphonate and Vitamin D on Atherosclerosis in Patients with Systemic Lupus Erythematosus
Kazumasa Ohmura, Masaru Kato, Toshiyuki Watanabe, Ryo Hisada, Masatoshi Kanda, Sanae Shimamura, Ikuma Nakagawa, Yuka Shimizu, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Premature atherosclerosis is one of the major complications of systemic lupus erythematosus (SLE). Preventing atherosclerosis is a key objective while monitoring patients with SLE.…
Abstract Number: 2168 • 2016 ACR/ARHP Annual Meeting
Metabolic Syndrome, All Cause Mortality and Atherosclerotic Cardiovascular Disease in Rheumatic Diseases
Marco Antivalle^1,2, Valentina Varisco², Alessandra Mutti², Alberto Batticciotto², Maria Chiara Ditto², Fabiola Atzeni³ and Piercarlo Sarzi-Puttini², ¹Rheumatology, Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ²Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, ³Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy
Background/Purpose: all-cause and cardiovascular mortality and cardiovascular morbidity are reportedly increased in rheumatic diseases, both inflammatory and non-inflammatory. Few studies, however have addressed the impact…
Abstract Number: 880 • 2016 ACR/ARHP Annual Meeting
Pilot Study of Microbubble Contrast-Enhanced Vascular Ultrasonography: A Novel Method of Detecting Large Vessel Vasculitis?
Kimberly P. Liang¹, Douglas P. Landsittel², Bernadette B. Sendon³, Donald M. Jones⁴, Suresh R. Mulukutla⁵, Steven E. Reis⁶, Ali Hakim Shoushtari⁷ and Larry W. Moreland⁸, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology & Clinical Immunology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁵Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Cardiology and Department of Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, ⁷Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: A key unmet need in the monitoring of disease activity in large vessel vasculitides (LVV), i.e., giant cell arteritis (GCA) and Takayasu arteritis…
Abstract Number: 2425 • 2016 ACR/ARHP Annual Meeting
The Vasculopathy of Juvenile Dermatomyositis (JDM); Evidence of Persistent Endothelial Injury, Hypercoagulability, Subclinical Inflammation and Increased Arterial Stiffness
Charalampia Papadopoulou^1,2, Ying Hong¹, Petra Krol^1,2, Yiannis Ioannou³, Clarissa Pilkington^2,4,5, Hema Chaplin⁶, Stephanie Simou¹, Marietta Charakida⁷, Lucy R Wedderburn^5,8,9, Paul Brogan¹⁰ and Despina Eleftheriou^1,8,11, ¹Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ²Paediatric Rheumatology, Great Ormond Street Hospital NHS Trust, London, United Kingdom, ³Rayne Institute, Arthritis Research UK Centre for Adolescent Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁴Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁵Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ⁶Centre for Adolescent Rheumatology, Arthritis Research UK, London, United Kingdom, ⁷Vascular Physiology Unit, Institute of Cardiovascular Science , University College London, London, United Kingdom, ⁸Paediatric Rheumatology Department, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁹Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ¹⁰Department of Paediatric Rheumatology, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ¹¹Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom
Background/Purpose: Vasculopathy is considered central to the pathogenesis of Juvenile Dermatomyositis (JDM). The interplay between persistent JDM-vasculopathy, traditional cardiovascular risk factors, exposure to corticosteroids, and…
Abstract Number: 1178 • 2016 ACR/ARHP Annual Meeting
Is Subclinical Atherosclerosis Prevalent in a French Patient Cohort with Systemic Lupus Erythematosus?
Tess Van Meerhaeghe¹, Alexis Mathian¹, Matthieu Wargny¹, Miguel HIe¹, Micheline Pha¹, Julien Haroche², Fleur Cohen¹, Thi-Huang Du Boutin¹ and Zahir Amoura¹, ¹Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ²Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France
Background/Purpose: Systemic lupus erythematosus (SLE) seems associated with an increased risk of cardiovascular disease. These data are mainly based on studies mostly from North America.…

« Previous Page
1
…
6
7
8
9
10
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].